Comparisons · Updated September 2026
Both raise NAD+. The real differences are how reliably each one gets into your cells, how much human trial data backs it up, and — for NMN specifically — a regulatory question that has nothing to do with biology.
As an Amazon Associate, LongevityLab earns from qualifying purchases.
NR (nicotinamide riboside) has the larger, more consistently replicated human trial base and a settled US regulatory status. NMN has one well-known trial with a specific metabolic benefit but sits in a contested regulatory gray zone. Neither has strong evidence for hard outcomes like lifespan — pick based on trial fit and risk tolerance, not marketing copy.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most heavily marketed NAD+ precursors on the market. Both sit one or two metabolic steps away from NAD+ itself, the coenzyme every cell needs for energy metabolism and for the sirtuin and PARP enzymes tied to cellular-aging research. The table below is the fast version; the sections after it explain why the numbers look the way they do.
| Factor | NMN | NR |
|---|---|---|
| Cellular entry | Debated — a dedicated transporter (Slc12a8) is confirmed in mice; human relevance is still unsettled | Established nucleoside-transporter uptake, then converted inside the cell |
| Human trial volume | Smaller, but includes one widely-cited 2021 trial | Larger and older body of published RCTs |
| Typical trial dose | 250–900mg/day | 300–1,000mg/day |
| US regulatory status | Contested since a 2022 FDA determination; unsettled | Established dietary-ingredient history (GRAS notice, NDI filings) |
| Price band | $$–$$$ | $$–$$$ |
| Best-evidenced signal | Improved muscle insulin sensitivity in one trial of prediabetic women | Consistent increases in blood NAD+ metabolome across several trials |
NMN’s strongest human data point is a 2021 trial in prediabetic postmenopausal women that found improved skeletal-muscle insulin sensitivity at 250mg/day — a genuinely interesting metabolic signal, not a lifespan claim. If you buy NMN, prioritize a batch-specific Certificate of Analysis confirming actual NMN content; purity issues have been documented in this fast-growing category.
Pros
Cons
NR has the deeper published trial history, including multi-week studies in healthy middle-aged and older adults that reliably raise blood NAD+ metabolome measures. The effect on harder outcomes — strength, cognition, cardiovascular markers — has been more modest and inconsistent than the NAD+ number itself, worth keeping in mind before expecting a dramatic subjective effect.
Pros
Cons
NAD+ (nicotinamide adenine dinucleotide) declines with age in preclinical models and is consumed by three main enzyme families: sirtuins, PARPs (DNA-repair enzymes), and CD38. NMN and NR are both “salvage pathway” precursors — instead of building NAD+ from scratch, the body converts either molecule through one or two enzymatic steps into NAD+ itself. NR is converted by NRK1/NRK2 enzymes into NMN, which is then converted into NAD+ by NMNAT enzymes; in other words, NR routes through NMN on its way to NAD+ regardless of which one you swallow. This shared endpoint is exactly why the two are compared so often — they are trying to solve the same problem from adjacent starting points, not competing mechanisms.
NR’s route into cells is comparatively well characterized: it crosses cell membranes via established nucleoside transporters before being converted inside the cell. NMN’s route is murkier. For years, researchers assumed NMN had to be dephosphorylated to NR before cells could take it up at all. A 2019 mouse study identified Slc12a8 as a dedicated NMN transporter in the gut, which reignited interest in NMN as a direct-acting molecule — but whether the same transporter plays a meaningful role in humans, and at what oral dose, remains an open question rather than a settled fact. Manufacturers of sublingual and liposomal NMN products argue their delivery formats sidestep the uptake question entirely by absorbing before first-pass gut metabolism; those claims rest mostly on pharmacokinetic data from the same companies selling the products, not independent trials matching the rigor of NR’s pharmacokinetic studies.
The single most-cited NMN human trial, published in Science in 2021, gave 250mg/day of NMN to prediabetic postmenopausal women for 10 weeks and found improved skeletal-muscle insulin sensitivity and muscle remodeling gene expression — a real, specific, and clinically interesting result, though from one trial in one population, not yet replicated at scale. NR’s trial base is broader: multiple randomized, placebo-controlled studies in healthy middle-aged and older adults, generally using 300–1,000mg/day for several weeks, consistently show significant increases in blood NAD+ metabolome measures. What they show less consistently is translation into functional outcomes people actually feel — several NR trials found no significant change in measures like aerobic capacity, insulin sensitivity, or cognitive testing despite the NAD+ increase. Read plainly: NR reliably moves a biomarker; NMN has one trial that moved an outcome. Neither has a large trial demonstrating an effect on human lifespan or a hard clinical endpoint, and anyone telling you otherwise is extrapolating from mouse data.
In 2022, the FDA stated that NMN had been authorized for investigation as a new pharmaceutical drug before it was marketed as a dietary supplement, which under US supplement law (DSHEA) can exclude an ingredient from lawful sale as a supplement — the same provision that affected NAC (N-acetylcysteine) in past years. That determination has been legally contested by industry groups, enforcement has been inconsistent, and several major retailers pulled some NMN listings while others continued selling it under various sourcing arrangements. As of this writing the legal status remains unresolved rather than closed in either direction.
Practically: NMN products are still widely available from multiple sellers, but availability and specific brand listings have shifted before without warning and could again. NR has no equivalent controversy and a much more stable regulatory footing as a marketed dietary ingredient. If regulatory stability matters to your buying decision, weigh that directly rather than assuming today’s availability is guaranteed to continue.
Both precursors land in a similar price band per month at typical doses — expect $$ to $$$ depending on brand, dose, and delivery format (capsule, sublingual, or liposomal). Standard NMN doses in the trial literature run 250–900mg/day; standard NR doses run 300–1,000mg/day. Neither dose has been optimized against a hard outcome, so more expensive high-dose products are not automatically better — they are simply following the trial range that happens to exist.
Choose NR if you want the more replicated evidence base, a settled regulatory picture, and are comfortable with NAD+-level increases as the main documented effect. View NR options on Amazon
Choose NMN if the specific insulin-sensitivity signal from the 2021 trial is the outcome you care about most, and you are comfortable buying an ingredient whose long-term US marketing status is not fully settled. View NMN options on Amazon
Whichever you pick, this is a NAD+-support decision, not a substitute for the fundamentals that most reliably support NAD+ status — sleep, exercise, and avoiding excess alcohol all measurably affect NAD+ metabolism and have far larger human evidence bases than either supplement.
It is sold widely, but its legal status is unsettled. In 2022 the FDA determined NMN had been authorized for investigation as a new drug before being marketed as a supplement, which can preclude lawful supplement marketing under US law. That determination has been contested and enforcement has been inconsistent, so treat NMN’s status as an open question rather than a settled fact in either direction.
Both raise blood NAD+ metabolome measures in published trials, but there is no large, dose-matched head-to-head trial comparing them directly, so there is no clean answer on magnitude. NR has more replicated studies showing the increase; NMN has fewer trials but one that also showed a specific functional benefit.
No published trial tests the combination directly. Because both feed into the same NAD+ synthesis pathway, stacking them is mechanistically plausible but unproven, and it roughly doubles your cost without demonstrated added benefit over either one alone.
NMN trials have commonly used around 250mg/day, with some studies going higher. NR trials have commonly used 300 to 1,000mg/day. These are research doses chosen for pharmacokinetic and safety reasons, not necessarily the doses proven to optimize any particular outcome.
Take the 7-question quiz to get your personalized supplement and lifestyle stack — tailored to your age, fitness level, and longevity concerns.
Take the QuizA 28-day fillable sleep log built around the seven levers that actually move sleep, so you test one per week and see what it did.